Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

Dexcom G5 Mobile CGM system receives FDA approval

Dexcom has received approval from the US Food and Drug Administration (FDA) for its G5 Mobile continuous glucose monitoring (CGM) system.

With wireless Bluetooth technology in its transmitter, the G5 Mobile CGM system has been developed for both adults and children as young as two years of age and sends glucose data directly to a smartphone.

The new transmitter is said to securely send crucial glucose information directly to an app on iOS-enabled devices for real-time diabetes management.

Dexcom president and CEO Kevin Sayer said: "Dexcom is rapidly advancing technology for continuous glucose monitoring devices to improve diabetes management.

"Since January, the company has introduced the G4 PLATINUM CGM with Share, apps to enable the first CGM on the Apple Watch and now the Dexcom G5 Mobile CGM."

The Dexcom G5 Mobile provides customizable alerts and features a built-in low glucose alarm (55mg/dL alarm) to warn patients of highs and lows.

Data from the G5 Mobile can be incorporated with Dexcom Clarity, a Cloud-based reporting software for personalized and easy-to-understand analysis of trends that are expected to improve diabetes management.

The company plans to make the new system available to customers from late September.